Outlook Therapeutics Stock News

ISELIN, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of

HC Wainwright reiterated their buy rating on shares of Outlook Therapeutics (NASDAQ:OTLK) in a research note issued to investors on Thursday, TipRanks reports. They currently have a $6.00 price objective on the stock. Separately, Zacks Investment Research raised shares of Outlook Therapeutics from a sell rating to a hold rating in a research note on []

Outlook Therapeutics (NASDAQ:OTLK) released its quarterly earnings results on Tuesday. The company reported ($0.09) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.06) by ($0.03), Fidelity Earnings reports. Shares of Outlook Therapeutics stock traded down $0.01 during trading hours on Thursday, hitting $1.38. 1,118 shares of the company were exchanged, compared to []

Pluristem Therapeutics (NASDAQ:PSTI) and Outlook Therapeutics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation and institutional ownership. Profitability This table compares Pluristem Therapeutics and Outlook Therapeutics’ net margins, return on equity and […]

Outlook Therapeutics, Inc. (NASDAQ:OTLK) with the stream of 2.84% also noticed, India Weidai Ltd. (NYSE:WEI) encountered a rapid change of -0.12% in the last hour of Fridays trading session. Outlook The post Latest Analysts Reports: Outlook Therapeutics, Inc. (NASDAQ:OTLK), Weidai Ltd. (NYSE:WEI) appeared first on Stocks Equity .

Rubius Therapeutics (NASDAQ:RUBY) and Outlook Therapeutics (NASDAQ:OTLK) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation. Valuation and Earnings This table compares Rubius Therapeutics and Outlook Therapeutics revenue, earnings per share []

Francesco Bandello, MD, FEBO, will present Phase 3 pivotal safety and efficacy data from the NORSE TWO registration trial Francesco Bandello, MD, FEBO, will present Phase 3 pivotal safety and efficacy data from the NORSE TWO registration trial

Outlook Therapeutics, Inc. (NASDAQ:OTLK) with the stream of -2.68% also noticed, India CooTek (Cayman) Inc. (NYSE:CTK) encountered a rapid change of 1.56% in the last hour of Fridays trading session. The post Traders should divert their intention on this Stock: Outlook Therapeutics, Inc. (NASDAQ:OTLK), CooTek (Cayman) Inc. (NYSE:CTK) appeared first on Stocks Equity .

Suber Huang, MD, MBA, FASRS will present data from the Phase 3 pivotal NORSE TWO registration trial Suber Huang, MD, MBA, FASRS will present data from the Phase 3 pivotal NORSE TWO registration trial

Corporate insiders buy penny stocks & these 10 are getting purchased in December 2021. The post 10 Penny Stocks To Buy In December According To Insiders appeared first on Penny Stocks to Buy, Picks, N

Outlook Therapeutics, Inc. (NASDAQ:OTLK) CEO C Russell Trenary III purchased 25,000 shares of the companys stock in a transaction that occurred on Monday, December 6th. The shares were acquired at an average cost of $1.39 per share, with a total value of $34,750.00. The acquisition was disclosed in a document filed with the Securities & []

Outlook Therapeutics, Inc. (NASDAQ:OTLK) COO Terry Dagnon bought 25,201 shares of the firms stock in a transaction on Monday, December 6th. The shares were purchased at an average cost of $1.38 per share, with a total value of $34,777.38. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is []

Outlook Therapeutics, Inc. (NASDAQ:OTLK) CEO C Russell Trenary III purchased 25,000 shares of the stock in a transaction dated Monday, December 6th. The shares were purchased at an average price of $1.39 per share, with a total value of $34,750.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is []

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Director Yezan Munther Haddadin purchased 10,000 shares of the stock in a transaction that occurred on Thursday, December 2nd. The shares were purchased at an average cost of $1.39 per share, with a total value of $13,900.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, []